Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Obstructive sleep apnea

18 evidence topics · 15 sources

US prevalence in 2024, AHI4 of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection by Clarivate and Apnimed authors)

“A literature-based systematic review was conducted to identify studies of OSA prevalence in adults using the AHI4 criteria (all apneas plus hypopneas associated with ≥4% oxygen desaturation).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“OSA was defined as having an AHI4 ≥ 5 events/hr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This translates to 32.4% overall prevalence in the US among adults aged 20 years and older, with 39.1% among males and 26.0% in females, adjusting for obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

US prevalence in 2007 to 2010, AHI of 5 or more and 15 or more with 4% desaturation hypopnea rule, adults aged 30 to 70 (Wisconsin Sleep Cohort extrapolated to NHANES body mass index distributions)

“A discernible reduction in the sum of thoracic plus abdomen respiratory inductance plethysmography amplitude associated with a 4% or more reduction in oxyhemoglobin saturation defined a hypopnea event.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These estimated prevalence rates represent substantial increases over the last 2 decades (relative increases of between 14% and 55% depending on the subgroup).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Summing over age × sex × BMI strata, we estimated the overall prevalence of mild to severe SDB (AHI ≥5) to be 26% (95% confidence interval: 24, 28) among person 30–70 years of age for the recent time period (2007–2010).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Similarly, the estimated overall prevalence of moderate to worse SDB (AHI ≥15) was 10% (95% confidence interval: 8, 11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We also estimate that 14% of men and 5% of women have an AHI ≥5 plus symptoms of daytime sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Global prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (ResMed-funded)
US prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (country table of the global estimate)
US prevalence projected from 2020 to 2050, AHI of 5 or more, adults aged 30 to 69, hypopnea scoring rule not stated (ResMed-funded simulation model)